Literature DB >> 2457809

Antigenic peptides recognized by T lymphocytes from AIDS viral envelope-immune humans.

J A Berzofsky1, A Bensussan, K B Cease, J F Bourge, R Cheynier, Z Lurhuma, J J Salaün, R C Gallo, G M Shearer, D Zagury.   

Abstract

T-lymphocyte immunity is likely to be an important component of the immune defence against the AIDS virus, because helper T cells are necessary for the antibody response as well as the cytotoxic response. We have previously predicted two antigenic sites of the viral envelope protein gp120 likely to be recognized by T lymphocytes, based on their ability to fold as amphipathic helices, and have demonstrated that these are recognized by T cells of mice immunized with gp120 (ref. 1). A peptide corresponding to one of these sites can also be induce immunity in mice to the whole gp120 protein. Because many clinically healthy seropositive blood donors have already lost their T-cell proliferative response to specific antigen, we tested the response to these synthetic peptides of lymphocytes from 14 healthy human volunteers who had been immunized with a recombinant vaccinia virus containing the AIDS viral envelope gene and boosted with a recombinant fragment. Eight of the 14 responded to one peptide, and four to the other peptide, not included in the boost. These antigenic sites recognized by human T cells may be useful components of a vaccine against AIDS. We also found a correlation between boosting with antigen-antibody complexes (compared to free antigen) and higher stimulation indices, suggesting a more effective method of immunization.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2457809     DOI: 10.1038/334706a0

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  39 in total

1.  Localization of CD4+ T cell epitope hotspots to exposed strands of HIV envelope glycoprotein suggests structural influences on antigen processing.

Authors:  S Surman; T D Lockey; K S Slobod; B Jones; J M Riberdy; S W White; P C Doherty; J L Hurwitz
Journal:  Proc Natl Acad Sci U S A       Date:  2001-04-03       Impact factor: 11.205

Review 2.  Cellular and humoral antigenic epitopes in HIV and SIV.

Authors:  D F Nixon; K Broliden; G Ogg; P A Broliden
Journal:  Immunology       Date:  1992-08       Impact factor: 7.397

3.  Inhibitory activity of HIV envelope gp120 dominates over its antigenicity for human T cells.

Authors:  F Manca; L Walker; A Newell; F Celada; J A Habeshaw; A G Dalgleish
Journal:  Clin Exp Immunol       Date:  1992-04       Impact factor: 4.330

4.  Synthetic peptides from a conserved region of gp120 induce broadly reactive anti-HIV responses.

Authors:  W J Morrow; W M Williams; A S Whalley; T Ryskamp; R Newman; C Y Kang; S Chamat; H Köhler; T Kieber-Emmons
Journal:  Immunology       Date:  1992-04       Impact factor: 7.397

5.  Analysis of human T-cell epitopes in the 19,000 MW antigen of Mycobacterium tuberculosis: influence of HLA-DR.

Authors:  A Faith; C Moreno; R Lathigra; E Roman; M Fernandez; S Brett; D M Mitchell; J Ivanyi; A D Rees
Journal:  Immunology       Date:  1991-09       Impact factor: 7.397

6.  Immunization against multiple viruses by using solid-matrix-antibody-antigen complexes.

Authors:  R E Randall; D F Young
Journal:  J Virol       Date:  1989-04       Impact factor: 5.103

7.  Targeting HIV Env immunogens to B cell follicles in nonhuman primates through immune complex or protein nanoparticle formulations.

Authors:  Jacob T Martin; Christopher A Cottrell; Aleksandar Antanasijevic; Diane G Carnathan; Benjamin J Cossette; Chiamaka A Enemuo; Etse H Gebru; Yury Choe; Federico Viviano; Stephanie Fischinger; Talar Tokatlian; Kimberly M Cirelli; George Ueda; Jeffrey Copps; Torben Schiffner; Sergey Menis; Galit Alter; William R Schief; Shane Crotty; Neil P King; David Baker; Guido Silvestri; Andrew B Ward; Darrell J Irvine
Journal:  NPJ Vaccines       Date:  2020-08-05       Impact factor: 7.344

8.  Synthetic peptides representing sequences within gp41 of HIV as immunogens for murine T- and B-cell responses.

Authors:  L E Brown; D O White; C Agius; B E Kemp; N Yatzakis; P Poumbourios; D A McPhee; D C Jackson
Journal:  Arch Virol       Date:  1995       Impact factor: 2.574

9.  Human immunodeficiency virus type 1 major neutralizing determinant exposed on hepatitis B surface antigen particles is highly immunogenic in primates.

Authors:  K Schlienger; M Mancini; Y Rivière; D Dormont; P Tiollais; M L Michel
Journal:  J Virol       Date:  1992-04       Impact factor: 5.103

Review 10.  Vaccine therapies for chronic hepatitis B: can we go further?

Authors:  Yumei Wen; Xuanyi Wang; Bin Wang; Zhenhong Yuan
Journal:  Front Med       Date:  2014-01-24       Impact factor: 4.592

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.